To summarize, the main drugs currently used for Alzheimer’s disease are cholinesterase inhibitors, which target acetylcholinesterase (AChE) and, in some cases, butyrylcholinesterase (BuChE), such as Donepezil, Rivastigmine, and galantamine; memantine, an NMDA receptor antagonist; and anti-Aβ peptide antibodies, such as aducanumab, lecanemab, and donanemab. Here, BCHE is linked to early-onset autosomal dominant Alzheimer disease.